Nektar Therapeutics saw the highest growth of 1.99% in patent filings in May and 1.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Nektar Therapeutics’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nektar Therapeutics has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 33% filings and 33% grants. The European Patent Office(EPO), Australia(AU), Israel(IL), and United States(US) patent Office are among the top ten patent offices where Nektar Therapeutics is filings its patents. Among the top granted patent authorities, Nektar Therapeutics has 33% of its grants in Australia(AU), 33% in Israel(IL) and 33% in United States(US).
Hanmi Science could be the strongest competitor for Nektar Therapeutics
In terms of grant share, Nektar Therapeutics stands in third position among its competitors. Hanmi Science and Nektar Therapeutics secured the top positions according to recent patent publication data.
Atopic dermatitis (atopic eczema) related patents lead Nektar Therapeutics portfolio
Nektar Therapeutics has highest number of patents in atopic dermatitis (atopic eczema).
For comprehensive analysis of Nektar Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

